Related Experiment Video
Updated: Jun 20, 2026
09:03
Human Mesenchymal Stem Cell Processing for Clinical Applications Using a Closed Semi-Automated Workflow
Published on: March 17, 2023
1.9K
Quality Control Optimization for Minimizing Security Risks Associated with Mesenchymal Stromal Cell-Based Product
Carmen Lúcia Kuniyoshi Rebelatto1,2, Lidiane Maria Boldrini-Leite1,2, Debora Regina Daga1,2
1Core for Cell Technology, School of Medicine, Pontifícia Universidade Católica do Paraná, Curitiba 80215-901, Brazil.
International Journal of Molecular Sciences
|August 26, 2023
Summary
Standardizing quality control for mesenchymal stromal cells (MSCs) is crucial for safe and effective regenerative medicine. This study developed robust assays to ensure MSC product consistency and patient safety.
Area of Science:
- Regenerative Medicine
- Cell Therapy
- Immunomodulation
Background:
- Mesenchymal stromal cells (MSCs) show therapeutic potential in regenerative medicine due to their regenerative and immunomodulatory properties.
- Challenges in translating MSC-based products include regulatory hurdles and scientific issues, necessitating standardized quality control.
- Ensuring reproducibility, safety, and efficacy of MSC products for patient administration is paramount.
Purpose of the Study:
- To develop standardized mesenchymal stromal cell (MSC)-based products for clinical use.
- To establish comprehensive quality control assays for MSC products.
- To address safety and efficacy concerns in MSC-based therapies.
Main Methods:
- Cell characterization, viability, immunogenicity, and differentiation assays.
- Safety testing including tissue factor (TF), microbiological, mycoplasma, endotoxin, genomic stability, and tumorigenicity tests.
- Potency testing assessing T-lymphocyte proliferation inhibition.
Main Results:
- Confirmed MSC marker expression, high cell viability (96.9%), and differentiation potential.
- Demonstrated low expression of HLA-DR and costimulatory molecules, but high TF/CD142 expression.
- Showed absence of pathogenic microorganisms, negative endotoxins, and no genotoxicity or tumorigenicity.
Conclusions:
- Standardized manufacturing and quality controls are essential to mitigate variability from donor heterogeneity.
- The developed assays ensure the safety and efficacy of MSC-based products.
- Optimized analytical and automated methods can further enhance the safety of MSC-based therapies.
